<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31951">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02124018</url>
  </required_header>
  <id_info>
    <org_study_id>UOA-PRESERVE1</org_study_id>
    <nct_id>NCT02124018</nct_id>
  </id_info>
  <brief_title>Risk Stratification in Patients With Preserved Ejection Fraction</brief_title>
  <acronym>PRESERVE-EF</acronym>
  <official_title>Post Myocardial Infarction Risk Stratification for Sudden Cardiac Death in Patients With Preserved Ejection Fraction: PRESERVE-EF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <authority>Greece: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the prevalence and the prognostic value of
      non-invasive indexes and programmed ventricular stimulation for sudden cardiac death in
      post-MI patients with LVEF &gt;40%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1000 asymptomatic post-MI patients&gt;40%, at least 40 days till 3 years post-MI,
      revascularized or without needing further revascularization (in any case without any
      evidence of ischemia) will be enrolled.

      The patients will be divided into two categories:

        1. Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit
           vessels &lt;70%) at 40 days post-MI (when LVEF&gt;40% will be re-assessed)

        2. Asymptomatic patients late (till 3 years) after MI (initially STEMI-NSTEMI at discharge
           Q-non Q) with LVEF&gt;40% right after a negative stress test or right after a negative for
           stenoses control coronary catheterization All patients will undergo non-invasive
           evaluation (ECG, Holter monitoring and 45-min high resolution recording). In case they
           fulfill at least one out of seven pre-specified criteria they will undergo programmed
           ventricular stimulation and ICD implantation (if inducible) All patients will be
           followed-up for 3 years for sudden cardiac death and its surrogate (appropriate ICD
           activation)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Sudden cardiac death, sustained VT, appropriate ICD activation</measure>
    <time_frame>From enrollment till 3 years of follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence and prognostic value (positive and negative) of non-invasive and invasive indexes for SCD and appropriate ICD activation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-invasive indexes variability</measure>
    <time_frame>1 year after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Repeat non-invasive indexes in fresh STEMI (first control in 40 days post-MI) 1 year later</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Predictors of VT inducibility</measure>
    <time_frame>Baseline evaluation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation of  non-invasive indexes (SAECG, Holter monitoring) with VT induction in PVS</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Post-MI patients</arm_group_label>
    <description>Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation will be performed in high-risk patients based on non-invasive evaluation.
ICD  implantation will be performed in patients with induced VT in programmed ventricular stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Programmed ventricular stimulation</intervention_name>
    <description>Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation</description>
    <arm_group_label>Post-MI patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD implantation</intervention_name>
    <description>ICD implantation in patients with induced VT in programmed ventricular stimulation</description>
    <arm_group_label>Post-MI patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1000 asymptomatic post-MI patients&gt;40%, at least 40 days post-MI, revascularized or
        without needing further revascularization (in any case without any evidence of ischemia)

        The patients will be divided into two categories:

          1. Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit
             vessels &lt;70%) at 40 days post-MI (when LVEF&gt;40% will be re-assessed)

          2. Asymptomatic patients late after MI (initially STEMI-NSTEMI at discharge Q-non Q)
             with LVEF&gt;40% right after a negative stress test or right after a negative for
             stenoses control coronary catheterization
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit
             vessels &lt;70%) at 40 days post-MI (when LVEF&gt;40% will be re-assessed)

          -  Asymptomatic patients late after MI (initially STEMI-NSTEMI at discharge Q-non Q)
             with LVEF&gt;40% right after a negative stress test or right after a negative for
             stenoses control coronary catheterization

        Exclusion Criteria:

          -  Episodes of sustained VT or aborted SCD 48 hours after the acute MI phase.

          -  Episodes of syncope within the last 6 months

          -  Cancer, liver failure (cirrhosis), end-stage renal disease

          -  Use of anti-arrhythmic drugs other than b-blockers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantinos Gatzoulis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Athens, Hippokration Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Cardiology Clinic, Hippokration Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Kostantinos A. Gatzoulis</investigator_full_name>
    <investigator_title>Assoc. Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Risk stratification</keyword>
  <keyword>Sudden cardiac death</keyword>
  <keyword>Preserved ejection fraction</keyword>
  <keyword>Programmed ventricular stimulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
